Our innovative medical aesthetic solutions pioneer advancements that redefine “better aging” and elevate life’s potential.
We have established an extensive and industry-leading product portfolio.Through strategic investments, acquisitions, and collaborative partnerships, we are advancing into global markets. Leveraging the synergistic effects of our product innovation and channel integration, we aspire to become a global leader in "Better Aging" solutions.
Six in-house developed Class III medical device products have been successively launched from 2012-2021. For consecutive years, we maintained the highest market share among domestic companies in China's dermal filler market.
After five years of independent R&D, EME® was launched in 2009, as China's first NMPA-approved HA-based dermal filler (Class III Medical Device), marking IMEIK’s establishment as the nation’s pioneer in injectable HA medical aesthetic products.
Imeik remains committed to rewarding investors with outstanding performance and sustainable growth, advancing green transformation with unwavering dedication, and fulfilling social responsibilities through a global vision. We weave a narrative of health and beauty through purposeful actions, harnessing technological innovation to create meaningful impact.
View More